The 24 weeks values of TRACP-5b for RhCTLA4-Ig group and infliximab group differed significantly from the baseline values in each group ( P < 0.05 ; P < 0.05 ) , whereas only the value for RhCTLA4-Ig group differed significantly from the 24 weeks value for the MTX group ( P < 0.01 ) .